SCHEMBL588669

SCHEMBL588669

Cc1c2ccc(N)cc2nn1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 5/20 0.46
MAPT P10636 4/20 0.46
NSD2 O96028 1/20 0.46
MEN1 O00255 7/20 0.42
KMT2A Q03164 7/20 0.42
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KDR P35968 2/20 0.40
KIT P10721 1/20 0.40
PDGFRA P16234 1/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17107839 0.98 KDM4E (0.44) ALDH1A1KDM4EMAPTNSD2MEN1
Hydrochloric Acid SCHEMBL27089989 0.98 KDM4E (0.44) ALDH1A1KDM4EMAPTNSD2MEN1
SCHEMBL7572894 0.85 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTNSD2MEN1
SCHEMBL27964997 0.81 MAPT (0.46) ALDH1A1KDM4EMAPTNSD2MEN1
SCHEMBL12163 0.80 KIT (0.41) ALDH1A1KDM4EMAPTCASP1CASP7
SCHEMBL13106176 0.77 KIT (0.44) KDM4EMEN1KMT2AKDRKIT
SCHEMBL26515852 0.77 PRNP (0.43) KDRKITPDGFRABTKCHRM4
SCHEMBL13106271 0.77 POLB (0.46) KDM4EMAPTKMT2ASMN1; SMN2HSD17B10
SCHEMBL2144329 0.77 PDGFRA (0.44) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL16574034 0.74 KIT (0.38) ALDH1A1KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751353-A 2, 3-Dimethyl-2H-indazole-6-amine and preparation method thereof 滁州市庆云医药有限公司 2025-04-04 CN claimed
CN-117924177-A Preparation method of pazopanib intermediate 2, 3-dimethyl-6-amino-2H-indazole and analogues thereof 南京杰运医药科技有限公司 2024-04-26 CN claimed
CN-114380748-B Synthesis method of 2, 3-dimethyl-6 amino-2H-indazole hydrochloride 南京杰运医药科技有限公司 2024-04-26 CN claimed
CN-116987066-A Pyrimidine compound and preparation method and application thereof 四川大学 2023-11-03 CN claimed
CN-109212042-B Analysis method for determining toxicity impurities of pezopyr hydrochloride gene by adopting liquid chromatography-mass spectrometry 齐鲁制药有限公司 2022-03-04 CN claimed
CN-108299304-A A method of preparing 2,3- dimethyl -2H- indazole -6- amine hydrochlorates 中国药科大学 2018-07-20 CN claimed
CN-103739550-B 2,3-dimethyl-6-urea-2H-indazole compounds and its preparation method and application CHINA PHARMACEUTICAL UNIVERSITY (CN) 2016-06-01 CN claimed
CN-103450085-B A kind of preparation method of pazopanib hydrochloride key intermediate ASYMCHEM MEDICAL GROUP (TIANJIN) INC. (CN) 2015-11-18 CN claimed
CN-103739550-A 2, 3-dimethyl-6-urea-2H-indazole compound and preparation method and application thereof UNIV CHINA PHARMA 2014-04-23 CN claimed
CN-103450085-A Preparation method of pazopanib hydrochloride key intermediate ASYMCHEM LAB TIANJIN CO LTD 2013-12-18 CN claimed
EP-2490536-A1 COMPOSITIONS AND PROCESSES Glaxo Wellcome Manufacturing Pte Ltd (SG) 2012-08-29 EP claimed
US-20120197019-A1 COMPOSITIONS AND PROCESSES GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2012-08-02 US claimed
WO-2011050159-A1 COMPOSITIONS AND PROCESSES GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2011-04-28 WO claimed
US-20070292513-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-12-20 US claimed
CN-120294252-A 2, 3-Dimethyl-6-amino-2H-indazole solution concentration detection device and detection method thereof 南京一苇医药科技有限公司 2025-07-11 CN disclosed
CN-120294252-A 2, 3-Dimethyl-6-amino-2H-indazole solution concentration detection device and detection method thereof 南京一苇医药科技有限公司 2025-07-11 CN disclosed
CN-119751353-A 2, 3-Dimethyl-2H-indazole-6-amine and preparation method thereof 滁州市庆云医药有限公司 2025-04-04 CN disclosed
EP-1515955-A2 CHEMICAL PROCESS SmithKline Beecham Corporation (US) 2005-03-23 EP disclosed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 US disclosed
WO-2003106416-A2 CHEMICAL PROCESS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197019-A1 COMPOSITIONS AND PROCESSES PIK3CA, PNP, PIK3CB ALDH1A1 1956/4885KDM4E 1943/4885MAPT 3565/4885
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators TYMS, TYMP, DPYD ALDH1A1 1108/4885KDM4E 1408/4885MAPT 3924/4885
US-20070292513-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 ALDH1A1 945/4885KDM4E 1688/4885MAPT 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.